循环LIFRSA/miR-1305/PTEN轴通过调节AKT酸化来减弱非小细胞肺癌中恶性细胞过程
Meina Jiang1, Huihui Bai1, Shuai Fang1
1Department of Biochemistry and Molecular Biology and Zhejiang Key Laboratory of Pathophysiology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, Zhejiang, 315211, China.
循环RNA LIFRSA (circLIFRSA) 在非小细胞肺癌 (NSCLC) 中被下调,抑制瘤生长并促进亡. circLIFRSA可以作为NSCLC的早期诊断生物标志物和治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- 非小细胞肺癌 (NSCLC) 往往呈现于晚期,限制了治疗的有效性.
- 新型循环RNA LIFRSA (circLIFRSA) 在NSCLC发病过程中的作用在很大程度上仍未被探索.
- 调查circLIFRSA参与PTEN/AKT通路对于了解NSCLC进展至关重要.
研究的目的:
- 研究circLIFRSA在非小细胞肺癌 (NSCLC) 的表达和功能.
- 阐明circLIFRSA影响NSCLC中PTEN/AKT信号通路的机制.
- 评估circLIFRSA作为NSCLC早期诊断生物标志物和治疗点的潜力.
主要方法:
- 微阵列分析和RT-qPCR用于确定NSCLC组织和细胞中的circLIFRSA表达水平.
- 细胞测试 (MTT,殖民地形成,流动细胞计) 评估了circLIFRSA对NSCLC细胞生长,增殖和亡的影响.
- 西方涂抹分析了PTEN和酸化AKT (pAKT) 的表达,以了解分子机制.
主要成果:
- 在NSCLC组织和细胞中,circLIFRSA的表达显著下调,与临床病理特征相关.
- circLIFRSA过度表达抑制了NSCLC细胞的增殖和生长,同时促进了细胞亡.
- 通过调节miR-1305/PTEN轴和抑制AKT酸化,circLIFRSA减弱了NSCLC恶性瘤.
结论:
- 循环LIFRSA/miR-1305/PTEN轴通过调节AKT酸化,在减弱NSCLC进展方面发挥着至关重要的作用.
- circLIFRSA显示出作为早期NSCLC诊断的有价值生物标志物的潜力.
- 在非小细胞肺癌治疗中,circLIFRSA 是一个有前途的治疗标.
更多相关视频
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades
Abnormal Proliferation
Inhibition of Cdk Activity
